PMID=26876532	O
EZH2	O
and	O
ZFX	O
oncogenes	O
in	O
malignant	O
behaviour	O
of	O
parathyroid	B
neoplasms	I
Several	O
studies	O
reported	O
somatic	O
mutations	O
of	O
many	O
genes	O
(	O
MEN1	O
,	O
CTNNB1	O
,	O
CDKIs	O
and	O
others	O
)	O
in	O
parathyroid	B
adenoma	I
,	O
although	O
with	O
different	O
prevalence	O
.	O

Recently	O
,	O
activating	O
mutations	O
of	O
the	O
EZH2	O
and	O
ZFX	O
oncogenes	O
were	O
identified	O
in	O
benign	O
parathyroid	B
adenoma	I
by	O
whole	O
exome	O
sequencing	O
.	O

The	O
same	O
mutations	O
had	O
been	O
found	O
in	O
blood	O
and	O
ovary	O
malignant	B
tumours	I
.	O

On	O
one	O
hand	O
,	O
this	O
result	O
raised	O
the	O
hypothesis	O
that	O
these	O
oncogenes	O
may	O
play	O
a	O
role	O
in	O
the	O
onset	O
of	O
parathyroid	B
tumour	I
,	O
but	O
it	O
would	O
also	O
suggest	O
they	O
may	O
be	O
involved	O
in	O
malignant	O
,	O
rather	O
benign	O
,	O
parathyroid	B
neoplasm	I
.	O

Our	O
aim	O
was	O
to	O
verify	O
the	O
occurrence	O
of	O
selected	O
mutations	O
of	O
the	O
EZH2	O
and	O
ZFX	O
genes	O
in	O
an	O
Italian	O
cohort	O
of	O
23	O
sporadic	O
parathyroid	B
carcinomas	I
,	O
12	O
atypical	O
and	O
45	O
typical	O
adenomas	O
.	O

DNA	O
was	O
extracted	O
from	O
paraffin	O
-	O
embedded	O
tissues	O
,	O
PCR	O
amplified	O
and	O
directly	O
sequenced	O
.	O

No	O
mutations	O
were	O
detected	O
in	O
the	O
coding	O
sequence	O
and	O
boundaries	O
of	O
both	O
genes	O
in	O
any	O
of	O
the	O
samples	O
.	O

Two	O
polymorphisms	O
of	O
the	O
EZH2	O
gene	O
were	O
identified	O
with	O
different	O
prevalence	O
:	O
the	O
rs2072407	O
variant	O
was	O
present	O
in	O
the	O
30	O
%	O
of	O
the	O
samples	O
,	O
in	O
keeping	O
with	O
the	O
overall	O
frequency	O
in	O
larger	O
populations	O
,	O
while	O
the	O
rs78589034	O
variant	O
,	O
located	O
close	O
to	O
the	O
5	O
'	O
end	O
of	O
the	O
exon	O
16	O
,	O
was	O
detected	O
in	O
only	O
one	O
proband	O
with	O
familial	O
isolated	O
hyperparathyroidism	B
;	O
we	O
investigated	O
the	O
possible	O
outcome	O
on	O
the	O
splicing	O
process	O
.	O

EZH2	O
and	O
ZFX	O
genes	O
do	O
not	O
seem	O
to	O
have	O
an	O
impact	O
on	O
the	O
onset	O
of	O
most	O
parathyroid	B
tumours	I
,	O
both	O
benign	O
and	O
malignant	O
,	O
though	O
further	O
studies	O
on	O
larger	O
cohorts	O
of	O
different	O
ethnicity	O
are	O
needed	O
.	O

PMID=27059693	O
Patient	O
-	O
Physician	O
Discordance	O
in	O
Global	O
Assessment	O
in	O
Rheumatoid	B
Arthritis	I
:	O
A	O
Systematic	O
Literature	O
Review	O
With	O
Meta	O
-	O
Analysis	O
The	O
integration	O
of	O
the	O
patient	O
in	O
therapeutic	O
decision	O
-	O
making	O
is	O
important	O
in	O
the	O
management	O
of	O
rheumatoid	B
arthritis	I
(	O
RA	B
)	O
,	O
but	O
the	O
patient	O
opinion	O
regarding	O
disease	O
status	O
may	O
differ	O
from	O
the	O
physician	O
's	O
opinion	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
assess	O
in	O
the	O
published	O
literature	O
the	O
frequency	O
and	O
drivers	O
of	O
patient	O
-	O
physician	O
discordance	O
in	O
global	O
assessment	O
in	O
RA	B
.	O

A	O
systematic	O
literature	O
review	O
of	O
all	O
articles	O
published	O
up	O
to	O
January	O
2015	O
in	O
Medline	O
or	O
Embase	O
,	O
reporting	O
discordance	O
in	O
RA	B
,	O
was	O
conducted	O
by	O
2	O
investigators	O
.	O

Discordance	O
was	O
defined	O
based	O
on	O
the	O
absolute	O
difference	O
of	O
patient	O
global	O
(	O
PGA	O
)	O
and	O
physician	O
global	O
assessments	O
(	O
PhGA	O
)	O
on	O
0	O
-	O
10	O
-	O
cm	O
scales	O
.	O

The	O
frequency	O
of	O
discordance	O
and	O
its	O
predictors	O
were	O
collected	O
in	O
each	O
study	O
.	O

Frequencies	O
of	O
discordance	O
were	O
pooled	O
by	O
meta	O
-	O
analysis	O
using	O
random	O
effect	O
.	O

In	O
all	O
,	O
12	O
studies	O
were	O
selected	O
(	O
i.e.	O
,	O
11,879	O
patients	O
):	O
weighted	O
mean	O
±	O
SD	O
age	O
was	O
55.1	O
±	O
13.9	O
years	O
,	O
weighted	O
mean	O
±	O
SD	O
disease	O
duration	O
was	O
10.4	O
±	O
9.3	O
years	O
,	O
and	O
80.7	O
%	O
were	O
women	O
.	O

The	O
value	O
of	O
the	O
difference	O
|	O
PGA	O
-	O
PhGA	O
|	O
defining	O
discordance	O
varied	O
between	O
≥0.5	O
cm	O
(	O
n	O
=	O
2	O
studies	O
)	O
to	O
≥3	O
cm	O
(	O
n	O
=	O
5	O
studies	O
)	O
;	O
the	O
weighted	O
mean	O
value	O
was	O
2.7	O
cm	O
.	O

The	O
pooled	O
percentage	O
of	O
patients	O
with	O
discordance	O
was	O
43	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
36%-51	O
%	O
;	O
range	O
25%-76	O
%	O
)	O
.	O

PGA	O
was	O
usually	O
higher	O
than	O
PhGA	O
.	O

The	O
drivers	O
of	O
PGA	O
were	O
pain	B
and	O
functional	O
incapacity	O
,	O
whereas	O
drivers	O
of	O
PhGA	O
were	O
joint	O
counts	O
and	O
acute	O
-	O
phase	O
reactants	O
.	O

Discordance	O
in	O
global	O
assessment	O
was	O
most	O
frequently	O
defined	O
as	O
a	O
difference	O
of	O
3	O
points	O
or	O
more	O
;	O
even	O
with	O
such	O
a	O
stringent	O
definition	O
,	O
up	O
to	O
half	O
the	O
patients	O
were	O
found	O
to	O
be	O
discordant	O
.	O

The	O
long	O
-	O
term	O
consequences	O
of	O
this	O
discordance	O
remain	O
to	O
be	O
determined	O
.	O

PMID=27117874	O
A	O
Randomized	O
Controlled	O
Noninferiority	O
Trial	O
of	O
Single	O
Dose	O
of	O
Oral	O
Dexamethasone	O
Versus	O
5	O
Days	O
of	O
Oral	O
Prednisone	O
in	O
Acute	O
Adult	O
Asthma	B
Oral	O
dexamethasone	O
demonstrates	O
bioavailability	O
similar	O
to	O
that	O
of	O
oral	O
prednisone	O
but	O
has	O
a	O
longer	O
half	O
-	O
life	O
.	O

We	O
evaluate	O
whether	O
a	O
single	O
dose	O
of	O
oral	O
dexamethasone	O
plus	O
4	O
days	O
of	O
placebo	O
is	O
not	O
inferior	O
to	O
5	O
days	O
of	O
oral	O
prednisone	O
in	O
treatment	O
of	O
adults	O
with	O
mild	O
to	O
moderate	O
asthma	O
exacerbations	O
to	O
prevent	O
relapse	O
defined	O
as	O
an	O
unscheduled	O
return	O
visit	O
for	O
additional	O
treatment	O
for	O
persistent	O
or	O
worsening	O
asthma	B
within	O
14	O
days	O
.	O

Adult	O
emergency	O
department	O
patients	O
(	O
aged	O
18	O
to	O
55	O
years	O
)	O
were	O
randomized	O
to	O
receive	O
either	O
a	O
single	O
dose	O
of	O
12	O
mg	O
of	O
oral	O
dexamethasone	O
with	O
4	O
days	O
of	O
placebo	O
or	O
a	O
5-	O
day	O
course	O
of	O
oral	O
prednisone	O
60	O
mg	O
a	O
day	O
.	O

Outcomes	O
including	O
relapse	O
were	O
assessed	O
by	O
a	O
follow	O
-	O
up	O
telephone	O
interview	O
at	O
2	O
weeks	O
.	O

One	O
hundred	O
seventy	O
-	O
three	O
dexamethasone	O
and	O
203	O
prednisone	O
subjects	O
completed	O
the	O
study	O
regimen	O
and	O
telephone	O
follow	O
-	O
up	O
.	O

The	O
dexamethasone	O
group	O
by	O
a	O
small	O
margin	O
surpassed	O
the	O
preset	O
8	O
%	O
difference	O
between	O
groups	O
for	O
noninferiority	O
in	O
relapse	O
rates	O
within	O
14	O
days	O
(	O
12.1	O
%	O
versus	O
9.8	O
%	O
;	O
difference	O
2.3	O
%	O
;	O
95	O
%	O
confidence	O
interval	O
-4.1	O
%	O
to	O
8.6	O
%	O
)	O
.	O

Subjects	O
in	O
the	O
2	O
groups	O
had	O
similar	O
rates	O
of	O
hospitalization	O
for	O
their	O
relapse	O
visit	O
(	O
dexamethasone	O
3.4	O
%	O
versus	O
prednisone	O
2.9	O
%	O
;	O
difference	O
0.5	O
%	O
;	O
95	O
%	O
confidence	O
interval	O
-4.1	O
%	O
to	O
3.1	O
%	O
)	O
.	O

Adverse	O
effect	O
rates	O
were	O
generally	O
the	O
same	O
in	O
the	O
2	O
groups	O
.	O

A	O
single	O
dose	O
of	O
oral	O
dexamethasone	O
did	O
not	O
demonstrate	O
noninferiority	O
to	O
prednisone	O
for	O
5	O
days	O
by	O
a	O
very	O
small	O
margin	O
for	O
treatment	O
of	O
adults	O
with	O
mild	O
to	O
moderate	O
asthma	O
exacerbations	O
.	O

Enhanced	O
compliance	O
and	O
convenience	O
may	O
support	O
the	O
use	O
of	O
dexamethasone	O
regardless	O
.	O

PMID=27172917	O
Malignancy	O
is	O
associated	O
with	O
microcalcification	O
and	O
higher	O
AP	O
/	O
T	O
ratio	O
in	O
ultrasonography	O
,	O
but	O
not	O
with	O
Hashimoto	B
's	I
thyroiditis	I
in	O
histopathology	O
in	O
patients	O
with	O
thyroid	B
nodules	I
evaluated	O
as	O
Bethesda	B
Category	I
III	I
(	O
AUS	O
/	O
FLUS	O
)	O
in	O
cytology	O
The	O
predictors	O
of	O
malignancy	O
are	O
important	O
for	O
the	O
decision	O
of	O
appropriate	O
management	O
in	O
nodules	B
with	O
atypia	O
of	O
undetermined	O
significance	O
/	O
follicular	O
lesion	O
of	O
undetermined	O
significance	O
(	O
AUS	O
/	O
FLUS	O
)	O
.	O

Our	O
aim	O
was	O
to	O
determine	O
the	O
ultrasonographical	O
,	O
clinical	O
,	O
and	O
biochemical	O
predictors	O
of	O
malignancy	O
in	O
these	O
patients	O
.	O

A	O
total	O
of	O
427	O
patients	O
with	O
cytologically	B
Bethesda	I
Category	I
III	I
(	O
AUS	O
/	O
FLUS	O
)	O
thyroid	B
nodules	I
were	O
included	O
in	O
this	O
retrospective	O
study	O
.	O

We	O
divided	O
the	O
nodules	B
into	O
two	O
subgroups	O
according	O
to	O
the	O
histopathology	O
as	O
benign	O
and	O
malignant	O
,	O
and	O
compared	O
the	O
preoperative	O
ultrasonographical	O
,	O
clinical	O
,	O
and	O
biochemical	O
findings	O
.	O

In	O
overall	O
,	O
427	O
patients	O
with	O
449	O
AUS	O
/	O
FLUS	O
nodules	B
who	O
had	O
undergone	O
surgery	O
,	O
the	O
rate	O
of	O
malignancy	O
was	O
23.4	O
%	O
(	O
105/449	O
)	O
.	O

When	O
evaluated	O
separately	O
,	O
the	O
rate	O
of	O
malignancy	O
was	O
25.8	O
%	O
in	O
nodules	B
with	O
AUS	O
(	O
82/318	O
)	O
and	O
17.6	O
%	O
in	O
nodules	B
with	O
FLUS	O
(	O
23/131	O
)	O
(	O
p	O
=	O
0.061	O
)	O
.	O

The	O
vast	O
majority	O
of	O
malignant	O
specimens	O
in	O
histopathology	O
consisted	O
of	O
papillary	B
thyroid	I
carcinoma	I
(	O
PTC	B
)	O
(	O
n	O
=	O
91	O
,	O
86.7	O
%	O
)	O
.	O

Preoperative	O
ultrasonographic	O
features	O
of	O
105	O
malignant	B
nodules	I
in	O
histopathology	O
were	O
compared	O
with	O
the	O
344	O
benign	O
nodules	O
in	O
histopathology	O
.	O

Anteroposterior	O
/	O
Transverse	O
(	O
AP	O
/	O
T	O
)	O
ratio	O
was	O
significantly	O
higher	O
in	O
malignant	O
group	O
compared	O
to	O
benign	O
group	O
(	O
p	O
=	O
0.013	O
)	O
.	O

In	O
multiple	O
logistic	O
analysis	O
,	O
we	O
found	O
that	O
higher	O
AP	O
/	O
T	O
ratio	O
and	O
microcalcification	O
were	O
independently	O
associated	O
with	O
malignancy	O
(	O
p	O
<	O
0.05	O
)	O
.	O

The	O
malignancy	O
-associated	O
cut	O
-	O
off	O
value	O
of	O
AP	O
/	O
T	O
ratio	O
at	O
maximum	O
sensitivity	O
and	O
specificity	O
was	O
≥0.81	O
.	O

We	O
did	O
not	O
find	O
any	O
correlation	O
between	O
malignancy	O
and	O
Hashimoto	B
's	I
thyroiditis	I
in	O
histopathology	O
in	O
multivariate	O
analysis	O
(	O
p	O
>	O
0.05	O
)	O
.	O

In	O
Bethesda	B
Category	I
III	I
nodules	I
with	O
higher	O
AP	O
/	O
T	O
ratio	O
and	O
microcalcification	O
,	O
surgery	O
might	O
be	O
considered	O
as	O
a	O
first	O
therapeutic	O
option	O
instead	O
of	O
repeat	O
fine	O
-	O
needle	O
aspiration	O
biopsy	O
or	O
observation	O
.	O

PMID=27234220	O
Safety	O
of	O
transradial	O
diagnostic	O
cardiac	O
catheterization	O
in	O
patients	O
under	O
oral	O
anticoagulant	O
therapy	O
Cardiac	O
catheterization	O
in	O
anticoagulated	O
patients	O
is	O
usually	O
performed	O
after	O
the	O
anticoagulation	O
has	O
been	O
withdrawn	O
,	O
at	O
least	O
in	O
the	O
previous	O
48h	O
,	O
and	O
sometimes	O
bridging	O
therapy	O
with	O
heparin	O
is	O
used	O
.	O

A	O
prospective	O
observational	O
study	O
including	O
489	O
patients	O
undergoing	O
transradial	O
catheterization	O
was	O
conducted	O
.	O

A	O
total	O
of	O
140	O
patients	O
were	O
under	O
acenocoumarol	O
(	O
group	O
A	O
)	O
and	O
they	O
were	O
compared	O
with	O
the	O
remainder	O
(	O
group	O
B	O
)	O
for	O
complications	O
after	O
the	O
procedure	O
(	O
bleeding	O
and	O
vascular	O
access	O
complications	O
)	O
.	O

Patients	O
in	O
group	O
A	O
were	O
older	O
(	O
74±12	O
years	O
vs.	O
68±17	O
years	O
,	O
p<0.01	O
)	O
and	O
the	O
main	O
indication	O
for	O
anticoagulation	O
was	O
atrial	B
fibrillation	I
(	O
58.6	O
%	O
)	O
.	O

No	O
complications	O
occurred	O
during	O
the	O
procedures	O
.	O

There	O
were	O
no	O
acute	O
bleedings	O
just	O
after	O
the	O
bandage	O
removal	O
.	O

During	O
the	O
first	O
24h	O
,	O
only	O
3	O
(	O
2.1	O
%	O
)	O
radial	O
occlusions	O
in	O
group	O
A	O
and	O
2	O
(	O
0.6	O
%	O
)	O
in	O
group	O
B	O
(	O
p=0.14	O
)	O
were	O
recorded	O
.	O

Hematomas	O
between	O
5	O
and	O
10	O
cm	O
appeared	O
in	O
5	O
%	O
of	O
the	O
group	O
A	O
vs.	O
4.6	O
%	O
in	O
group	O
B.	O
During	O
the	O
1	O
-	O
month	O
follow	O
-	O
up	O
period	O
,	O
one	O
more	O
radial	O
occlusion	O
in	O
each	O
group	O
was	O
recorded	O
and	O
there	O
were	O
4	O
(	O
1.1	O
%	O
)	O
additional	O
mild	O
hematomas	O
in	O
group	O
B	O
and	O
none	O
in	O
group	O
A	O
(	O
p=0.48	O
)	O
.	O

Performing	O
a	O
transradial	O
diagnostic	O
cardiac	O
catheterization	O
without	O
removal	O
of	O
the	O
oral	O
chronic	O
anticoagulation	O
appears	O
safe	O
in	O
patients	O
under	O
acenocumarol	O
therapy	O
.	O

PMID=27235789	O
Elective	O
Nephron	O
Sparing	O
Surgery	O
Decreases	O
Other	O
Cause	O
Mortality	O
Relative	O
to	O
Radical	O
Nephrectomy	O
Only	O
in	O
Specific	O
Subgroups	O
of	O
Patients	O
with	O
Renal	B
Cell	I
Carcinoma	I
There	O
is	O
no	O
consensus	O
regarding	O
a	O
protective	O
effect	O
on	O
mortality	O
due	O
to	O
a	O
cause	O
other	O
than	O
cancer	B
in	O
patients	O
treated	O
with	O
elective	O
nephron	O
sparing	O
surgery	O
relative	O
to	O
their	O
radical	O
nephrectomy	O
counterparts	O
.	O

We	O
test	O
whether	O
the	O
protective	O
effect	O
of	O
nephron	O
sparing	O
surgery	O
relative	O
to	O
radical	O
nephrectomy	O
is	O
universal	O
or	O
present	O
in	O
specific	O
subgroups	O
of	O
patients	O
.	O

A	O
collaborative	O
database	O
of	O
5	O
institutions	O
was	O
queried	O
to	O
evaluate	O
1,783	O
patients	O
without	O
chronic	B
kidney	I
disease	I
diagnosed	O
with	O
a	O
clinical	O
T1	O
renal	O
mass	O
that	O
was	O
treated	O
with	O
nephron	O
sparing	O
surgery	O
or	O
radical	O
nephrectomy	O
.	O

Multivariable	O
Cox	O
regression	O
analysis	O
was	O
done	O
to	O
assess	O
the	O
impact	O
of	O
surgery	O
type	O
(	O
nephron	O
sparing	O
surgery	O
vs	O
radical	O
nephrectomy	O
)	O
on	O
other	O
cause	O
mortality	O
after	O
adjustment	O
for	O
patient	O
and	O
cancer	B
characteristics	O
.	O

Interaction	O
terms	O
were	O
used	O
to	O
test	O
the	O
hypothesis	O
that	O
the	O
impact	O
of	O
surgery	O
type	O
varies	O
according	O
to	O
specific	O
subcohorts	O
of	O
patients	O
.	O

Ten	O
-	O
year	O
other	O
cause	O
mortality	O
-free	O
survival	O
rates	O
were	O
90	O
%	O
and	O
88	O
%	O
after	O
nephron	O
sparing	O
surgery	O
and	O
radical	O
nephrectomy	O
,	O
respectively	O
.	O

In	O
the	O
overall	O
population	O
radical	O
nephrectomy	O
was	O
not	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
other	O
cause	O
mortality	O
on	O
multivariable	O
analysis	O
compared	O
to	O
nephron	O
sparing	O
surgery	O
(	O
HR	O
0.91	O
,	O
95	O
%	O
CI	O
0.6	O
-	O
1.38	O
,	O
p	O
=	O
0.6	O
)	O
.	O

However	O
,	O
radical	O
nephrectomy	O
increased	O
the	O
risk	O
of	O
other	O
cause	O
mortality	O
according	O
to	O
the	O
increasing	O
baseline	O
Charlson	O
comorbidity	O
index	O
(	O
interaction	O
test	O
p	O
=	O
0.0008	O
)	O
.	O

For	O
example	O
,	O
in	O
a	O
patient	O
with	O
a	O
Charlson	O
comorbidity	O
index	O
of	O
4	O
the	O
probability	O
of	O
10	O
-	O
year	O
other	O
cause	O
mortality	O
-free	O
survival	O
was	O
86	O
%	O
after	O
nephron	O
sparing	O
surgery	O
and	O
60	O
%	O
after	O
radical	O
nephrectomy	O
.	O

Elective	O
nephron	O
sparing	O
surgery	O
does	O
not	O
improve	O
other	O
cause	O
survival	O
relative	O
to	O
radical	O
nephrectomy	O
consistently	O
in	O
all	O
patients	O
with	O
kidney	O
cancer	O
.	O

Patients	O
who	O
are	O
more	O
ill	O
with	O
relevant	O
comorbidities	O
are	O
those	O
who	O
benefit	O
the	O
most	O
from	O
nephron	O
sparing	O
surgery	O
in	O
terms	O
of	O
other	O
cause	O
mortality	O
.	O

PMID=27237609	O
Prospective	O
study	O
of	O
dietary	O
Non	O
Enzymatic	O
Antioxidant	O
Capacity	O
on	O
the	O
